Ozempic, Wegovy Gain Popularity

This is a U.S. news story, published by Gizmodo, that relates primarily to Wegovy news.

U.S. news

For more U.S. news, you can click here:

more U.S. news

Wegovy news

For more Wegovy news, you can click here:

more Wegovy news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

Gizmodo news

For more news from Gizmodo, you can click here:

more news from Gizmodo

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

obesity medicine

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest older obesity drugs news, obesity treatment news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

diabetes drug Ozempic

Gizmodo

•

How Ozempic Worksâand Whatâs Still a Mystery

Summary

Nutrition label

74% Informative

The active ingredient in Novo Nordisk’s Ozempic and Wegovy is semaglutide, which belongs to a group of drugs known as GLP-1RAs .

GLP is one of several hormones that play a key role in regulating our metabolism and hunger.

Natural GLP1 doesn’t last very long in our body, with a half -life of only minutes .

Lab-made proteins have been developed that can activate the same receptors that GLP 1 does, while lasting much longer in our system.

SemagLutide in particular boasts a week , well above the 13 or so hours for exenatide.

GLP-1RAs are one especially potent lever that we can use to address the biological underpinnings of obesity, if not the only one available.

In large-scale clinical trials, people taking Wegovy were shown to lose around 15% of their body weight over a year.

GLP-1RAs do appear to be safe and effective for the majority of patients taking them.

The adult obesity rate in the U.S. is currently around 42% , and the prevalence of obesity has continued to rise in many states even since the approval of Wegovy in 2021 .

VR Score

Informative language

Neutral language

Article tone

informal

Language

English

Language complexity

Offensive language

possibly offensive

Hate speech

not hateful